Helius Medical Technologies Inc represents values of innovation, excellence, and patient-centered care. With a strong corporate philosophy focused on advancing neurorehabilitation and improving patient outcomes, Helius Medical Technologies is committed to developing and delivering cutting-edge medical technologies. The company harnesses the power of its proprietary PoNS™ device, which combines neurostimulation with therapeutic exercises, to provide non-invasive treatment options for patients suffering from neurological symptoms. Helius Medical Technologies Inc strives to empower patients and healthcare providers with state-of-the-art solutions that have the potential to transform lives. Through dedication to research, development, and collaboration, the company aims to make a lasting and positive impact on the field of neurorehabilitation.

Helius Medical Technologies Inc is primarily present in the United States and Canada. As a leading medical technology company, Helius focuses on neurological wellness by developing and commercializing innovative products. With headquarters in Newtown, Pennsylvania, Helius operates in various regions across North America, aiming to provide advanced neurostimulation solutions. This includes the PoNS™ device, a non-invasive neuromodulation device for the treatment of neurological symptoms caused by disease or trauma. By combining medical expertise and cutting-edge technology, Helius Medical Technologies Inc contributes to improving patient outcomes throughout the United States and Canada.

Helius Medical Technologies Inc has achieved several significant milestones. One notable achievement is the FDA clearance of their PoNS™ device for the treatment of neurological symptoms caused by multiple sclerosis (MS) and traumatic brain injury (TBI). The company has also expanded its clinical trial programs and collaborations to further explore the potential of their innovative technology in other areas, such as stroke rehabilitation. Additionally, Helius Medical Technologies Inc has successfully raised capital to support its research and development efforts, demonstrating investor confidence in the company's vision and potential.

Helius Medical Technologies Inc is a leading neurotech company focused on developing groundbreaking non-invasive treatments. Founded in 2014, the company is driven by a mission to expand and advance the understanding, treatment, and application of neurological disorders. Helius Medical Technologies Inc is renowned for its innovative device, the Portable Neuromodulation Stimulator (PoNS), which has shown promising results in various clinical trials. This breakthrough technology aims to enhance neuroplasticity, encouraging healing and recovery for patients with neurological conditions. With a commitment to improving patients' quality of life, Helius Medical Technologies Inc continues to revolutionize the field of neuro-rehabilitation through cutting-edge innovations and research.

The main competitors of Helius Medical Technologies Inc in the market are NeuroMetrix, Inc and Neuromod Devices Limited.

Helius Medical Technologies Inc is primarily active in the healthcare industry.

Helius Medical Technologies Inc operates as a medical technology company. Its business model focuses on the development, licensing, and commercialization of neurological technologies. The company primarily offers its proprietary neurostimulation technology platform, known as PoNS™ (Portable Neuromodulation Stimulator), which is designed to enhance neural activity in the brain. Helius Medical Technologies aims to address unmet medical needs and provide innovative solutions for patients suffering from neurological symptoms caused by disease or trauma. With a strong commitment to research and development, the company strives to improve patient outcomes and advance the field of neurology.

KGV Helius Medical Technologies iznosi −0,03.

Koeficijent cijene i prometa Helius Medical Technologies iznosi 1,16.

AlleAktien Qualitätsscore za Helius Medical Technologies je 3/10.

Promet očekivana Helius Medical Technologies iznosi 477.360,00 USD.

Dobit očekivana Helius Medical Technologies iznosi −18,41 mil. USD.

The business model of Helius Medical Technologies focuses on the development and marketing of innovative products and services to improve the rehabilitation of neurological diseases. The company specializes in neurorehabilitation, offering a therapy called PoNS (Portable Neuromodulation Stimulator) that stimulates nerves in the brain through electronic impulses sent to the tongue. This therapy can improve motor and cognitive abilities in patients with conditions such as stroke, traumatic brain injury, or multiple sclerosis. Helius Medical Technologies is also involved in neuroscience research and development, collaborating with leading research institutions and clinical studies. Additionally, the company offers telemedicine services through their Helius Tele-Rehabilitation program, allowing patients to participate in therapy sessions from home using a PoNS stimulator and iPad. Overall, Helius Medical Technologies aims to continually innovate and expand its business through research and development, patent acquisition, and collaborations with clinicians and researchers. Its goal is to improve the lives of millions of individuals worldwide.

Helius Medical Technologies isplaćuje dividendu od 0 USD raspoređenu preko isplata godišnje.

Dividenda za Helius Medical Technologies trenutno se ne može izračunati ili tvrtka ne isplaćuje dividendu.

ISIN od Helius Medical Technologies je US42328V6039.

WKN od Helius Medical Technologies je A2JB8E.

Oznaka burze tvrtke Helius Medical Technologies je HSDT.

U posljednjih 12 mjeseci Helius Medical Technologies je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Helius Medical Technologies će vjerojatno isplatiti dividendu u iznosu od 0 USD.

Trenutni prinos dividende od Helius Medical Technologies iznosi .

Helius Medical Technologies isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Helius Medical Technologies je isplatio dividendu svake godine u posljednjih 0 godina.

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Helius Medical Technologies se pripisuje sektoru 'Zdravlje'.

Da bi primili posljednju dividendu od Helius Medical Technologies od 21. 12. 2024. u iznosu od 0 USD, trebali ste imati dionicu u portfelju prije Ex-dana 21. 12. 2024..

Posljednja isplata dividende izvršena je 21. 12. 2024..

U godini 2023 su od Helius Medical Technologies 0 USD isplaćene kao dividende.

Dividende od Helius Medical Technologies isplaćuju se u USD.